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noside 3g/m2 x 6 and TBI 1200-1400 cGy. In addition, AD
recipients received either ex vivo partial T-cell depletion or
Campath to achieve in vivo T-cell depletion in an effort to
reduce the risk of GVHD. Five AD patients died; 4 patients in
chronic phase and 1 patient in accelerated phase prior to trans-
plant. One patient died from recurrent disease and the other 4
from complications of therapy: 1 engraftment failure; 1 poor
engraftment and fungal disease; 1 cryptosporidium parasitemia;
and 1 pulmonary hemorrhage with viral infections. After trans-
plantation, 30% in each group (MSD and AD) required addi-
tional Gleevec or donor leukocyte infusions for BCR/ABL pos-
itivity. The Kaplan-Meier estimate of disease-free survival at 2
years was 78% for the entire cohort: 100% for the MSD group
and 56% for the AD group. Only 1 patient (AD recipient)
developed grade 3-4 acute GVHD and only 1 patient (AD
recipient) developed extensive, chronic GVHD. We conclude
that stem cell transplantation provides effective leukemia con-
trol and potential cure even for patients with advanced disease
who lack an MSD. Regimen-related mortality remains an im-
pediment to improved outcome for pediatric CML patients
receiving stem cells from unrelated or mismatched donors.
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ASSESSMENT OF ADENOVIRUS SUBGENERA PREVALENCE BY REAL-
TIME PCR IN IMMUNOCOMPROMISED PATIENTS
Duncan, K.1, Reddy, S.1, Vats, A.2, Kleiboeker, S.1 1ViraCor Labora-
tories, Lee’s Summit, MO; 2Children’s Hospital of Pittsburgh, Division
of Pediatric Nephrology, Pittsburgh, PA.
Background: Adenoviruses (Adv) are double-stranded DNA
viruses that can be classiﬁed by serotypes (1-51), which are
grouped into six subgenera (A-F). Within the different subgen-
era, viral characteristics vary in terms of host range, disease
type, and genetic composition. Real-time PCR has proven to be
a rapid, sensitive, and speciﬁc way to analyze the variable re-
gions of the Adv genome for subgenera determination. Using
this methodology, we determined the prevalence of Adv sub-
genera in a variety of Adv-positive clinical specimens collected
from immunocompromised patients.
Methods: Initially we utilized real time PCR TaqMan®
chemistry to quantify AdV DNA in clinical specimens using a
single pair of primers and a minor groove-binding probe (MGB)
designed to detect and quantitate all 51 Adv serotypes. From
specimens that were determined to be Adv-positive with this
assay, we randomly selected twenty-eight plasma, twenty-one
urine, and three fecal/rectal samples for Adv subgenera classi-
ﬁcation. Each specimen was analyzed by six individual Taq-
Man® assays (Watzinger et al., J. Clin. Microbiol 42:5189),
each designed to speciﬁcally detect all known serotypes within
each of the six subgenera.
Results: Plasma specimens tested with the pan-AdV assay had
viral loads ranging from 7.34101 – 5.73106 copies/ml. Urine
specimens had viral loads ranging from 1.24102 – 1.57107
copies/ml, and fecal/rectal samples had viral loads ranging from
9.04103 – 1.02.x107 0107 copies/ml. Subgenera determina-
tion for plasma demonstrated that 21% (6 samples) were Sub-
genus B, and 79% (22 samples) were Subgenus C. Results from
urine demonstrated that 81% (17 samples) were Subgenus B,
14% (3 samples) were Subgenus C, and 5% (1 sample) was
Subgenus D. Of the three fecal/rectal samples two were Subge-
nus D and one was Subgenus F. Using Fisher’s Exact Test, the
subgenera distribution among plasma and urine was determined
to be signiﬁcantly different (P0.0001; odds ratio20.78, 95%
CI: 4.526 to 95.38).
Conclusion: Results of this study demonstrate that the prev-
alence of AdV subgenera differ signiﬁcantly among specimen
types collected from immunocompromised patients. The pre-
dominant subgenus identiﬁed in urine was B while the predom-
inant subgenus identiﬁed in plasma was C. These results support
previous ﬁndings for prevalence in plasma and urine. Real-time
PCR technology provides an efﬁcient means to accurately diag-
nose Adenovirus infections and identiﬁcation of AdV subgenera.
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SUCCESSFUL HSCT AFTER MULTIVISCERAL TRANSPLANTATION
Kleiner, G.I.1, Gonzalez-Brito, M.1, Weppler, D.2, White, E.1,
Simon, N.3, David, A.2, Selvaggi, G.2, Kato, T.2, Shariatmadar, S.4,
Tzakis, A.2 1Department of Pediatrics, University of Miami, Miami,
FL; 2Division of Liver-GI Transplantation, University of Miami, Mi-
ami, FL; 3Jackson Memorial Hospital, Miami, FL; 4Department of
Pathology, University of Miami, Miami, FL.
Severe aplastic anemia following liver transplantation is a rare
phenomenon. We report the case of an eight year old girl who
developed SAA following multivisceral transplantation. The pa-
tient was diagnosed with intestinal pseudo obstruction and un-
derwent modiﬁed multivisceral transplant (stomach, pancreas,
spleen, small and large intestine) in December 2005. Post op-
erative course was uncomplicated but the patient developed SAA
six months later. There was no response to growth factors or
increased immunosuppression. The patient was housed in the
Pediatric ICU. Her brother was found to be HLA identical and
the patient underwent conditioning with Fludaribine 25mg/
m25, Cyclosphosphamide 50mg/kg x4, and ATG 30mg/kg x3.
She received 1.33  10e8 mnc/kg bone marrow. The patient
tolerated chemotherapy well. Post transplant course was com-
plicated by VRE treated with parenteral antibiotics and granu-
locyte transfusion support. The patient engrafted on day16.
FISH XY revealed 100% donor. We conclude that this reduced
intensity regimen may be effective in SAA cases following solid
organ transplantation.
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CORRELATION BETWEEN INFUSED MONONUCLEAR CELLS (MNC) AND
TRANSPLANT OUTCOME IN PEDIATRIC CORD BLOOD TRANSPLANTA-
TION (CBT). A STUDY OF 92 SINGLE CBT DONE AT CHILDREN’S
MEMORIAL HOSPITAL, CHICAGO, IL
Merchant, M.1, Olszewski, M.1, Huang, W.1, Duerst, R.1,2,
Jacobsohn, D.1,2, Kletzel, M.1,2 1Children’s Memorial Hospital, Chicago,
IL; 2Northwestern University Feinberg School of Medicine, Chicago, IL.
Objective:
To evaluate if there is a correlation between infused MNC cell
dose and transplant outcome in pediatric CBT.
Method:
Between January 1995 and February 2006, 125 CBT were carried
out at Children’s Memorial Hospital. 15 patients already had a
previous transplant and 18 patients required a subsequent trans-
plant after the initial CBT failed (primary or secondary graft failure
or relapse). Remaining 92 patients (43 female, 49 male) who un-
derwent a single CBT were evaluated in this study. 26 patients had
non-malignant conditions (SCID 7, HPCS 5, Wiskott-Aldrich
syndrome 3, 2 each of Aplastic anemia, Hurler’s syndrome and
Osteopetrosis, others 5) and 66 had malignancy (ALL 33, AML 21,
MDS 5, 2 each of Non-Hodgkin’s lymphoma and JMML, others
3). Disease status for malignancy at time of CBT was PR 7, CR1
24, CR2 28, CR 3/3 7. 69 patients received myeloablative con-
ditioning regimen (fTBI, VP-Cy, or Thiotepa. 4 patients received
Busulphan in place fTBI); 23 patients had reduced intensity con-
ditioning (Busulphan, Fludarabine, ATG). The median age at
transplant was 34.5 months (range 1 to 200), with median HLA
match of 4:6; ratio of cord sex was 53 female to 39 male. The
median MNC cell dose infused was 0.57  108/kg (range 0.08-
2.83). See table.
Results/Outcome:
Overall, 63 (68.5%) patients showed ANC engraftment (500
cells/	L), 58 (63.0%) showed PLT engraftment (20,000 cells/
	L) in a median of 24 (range 15- 60) and 44 (range 14- 105) days
respectively. 22 patients (23.9%) died within day 100 of CBT
from transplant related mortality. 13 patients (14.1%) had a re-
lapse. Overall 57 patients (62%) are event free at the present time
with an overall survival (OS) of 706 days.
Conclusions:
1. As the MNC cell dose increases, days required to achieve
engraftment (both ANC and PLT) decrease, showing these out-
come parameters are cell dose dependent.
2. Group 1 received the lowest cell dose (0.08- 0.29  108/kg)
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